InDex Pharmaceuticals Q1’22: Brief Report Comment - Redeye
Redeye leaves its comments on InDex Pharmaceuticals following its Q1 2022 report. Recent news includes management changes and minor news related to CONCLUDE, which seems to be progressing according to plan.
ANNONS
Redeye leaves its comments on InDex Pharmaceuticals following its Q1 2022 report. Recent news includes management changes and minor news related to CONCLUDE, which seems to be progressing according to plan.